18133-18-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Oxo-1-phenyl-pyrrolidine-2-carboxylic acid is used as an anti-fibrotic and anti-inflammatory agent for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It works by inhibiting the synthesis of transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α), which are involved in the progression of fibrosis.
Used in Medical Research:
5-Oxo-1-phenyl-pyrrolidine-2-carboxylic acid is used as a research compound to study its potential effects on reducing inflammation and oxidative stress. This helps in understanding its therapeutic potential for various fibrotic and inflammatory conditions.

Upstream product

• 146500-35-8 methyl 1-phenyl-5-oxo-2-pyrrolidinecarboxylate 
• 108-86-1 bromobenzene 
• 4931-66-2 methyl 5-oxopyrrolidine-2-carboxylate 
• 149-87-1 Pyroglutamic acid 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1252657-20-7 5-{[4-(2-tert-Butylphenyl)piperazin-1-yl]carbonyl}-1-phenylpyrrolidin-2-one 

Relevant academic research and scientific papers

Synthesis of C-ring-modified blebbistatin derivatives and evaluation of their myosin II ATPase inhibitory potency

(S)-Blebbistatin is a micromolar myosin II ATPase inhibitor that is extensively used in research. In search of analogs with improved potency, we have synthesized for the first time C-ring modified analogs. We introduced hydroxymethyl or allyloxymethyl fun

DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES

The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

Novel Receptor Antagonists and Their Methods of Use

The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.